Kourie HR, Mavroudakis N, Aftimos P, Piccart M. Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. World J Clin Oncol 2017; 8(5): 425-428 [PMID: 29067280 DOI: 10.5306/wjco.v8.i5.425]
Corresponding Author of This Article
Hampig Raphael Kourie, MD, MSc, Oncology Department, Faculty of Medicine, Saint Joseph University, Damascus Street, Beirut 880, Lebanon. hampig.kourie@usj.edu.lb
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Oct 10, 2017; 8(5): 425-428 Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.425
Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer
Hampig Raphael Kourie, Nicolas Mavroudakis, Philippe Aftimos, Martine Piccart
Hampig Raphael Kourie, Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut 880, Lebanon
Nicolas Mavroudakis, Philippe Aftimos, Martine Piccart, Oncology Department, Jules Bordet Institute, 1000 Brussels, Belgium
Author contributions: Kourie HR and Aftimos P initiated and wrote this case; Mavroudakis N and Piccart M reviewed and commented on this paper.
Institutional review board statement: The Bordet Institute’s Ethics Committee provides a favorable opinion on the disclosure/publication of a patient clinical history to be reported as a “case report”.
Informed consent statement: The authors undertake to respect the confidentiality, anonymity as well as the quality of the published information, The authors have recorded the consent of the patient in his medical record.
Conflict-of-interest statement: The authors confirm that they do not have any conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hampig Raphael Kourie, MD, MSc, Oncology Department, Faculty of Medicine, Saint Joseph University, Damascus Street, Beirut 880, Lebanon. hampig.kourie@usj.edu.lb
Telephone: +961-3-321899 Fax: +961-1-877787
Received: December 3, 2016 Peer-review started: December 5, 2016 First decision: February 17, 2017 Revised: July 24, 2017 Accepted: August 15, 2017 Article in press: August 16, 2017 Published online: October 10, 2017 Processing time: 295 Days and 22.8 Hours
Abstract
Charcot-Marie-Tooth (CMT) neuropathy is the most common hereditary cause of neuropathy. Diagnosis is usually not made during the childhood but in adolescence or late adulthood. It is reported in the literature that some neurotoxic chemotherapeutical agents can reveal an asymptomatic CMT IA hereditary neuropathy. To our knowledge, we report here the first case of CMT IA revealed in a 55-year-old woman after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This case stresses again the necessity to obtain a complete personal and familial anamnesis and to perform a neurologic examination before the administration of neurotoxic chemotherapeutical agents to prevent the clinical expression of these hereditary neuropathies.
Core tip: This case report represents the first case of Charcot-Marie-Tooth IA revealed after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This paper will help to focus on the revelation of rare hereditary neuropathies after the administration of chemotherapies.
